First-quarter earnings for German biosimilar developer, Formycon AG, has shown that early measures taken to mitigate the effects of the coronavirus disease 2019 (COVID-19) pandemic have paid off.
Biosimilar manufacturer Formycon AG’s early action in the face of the coronavirus disease 2019 (COVID-19) pandemic has helped it adapt to the prevailing situation as operational development largely stayed on track, according to the company’s first quarter earnings for 2020.
The company was able to act early to implement measures to protect employees during the course of the pandemic and ensure that their projects didn’t fall behind.
“We are pleased about the good start to the new financial year. Despite the ongoing COVID-19 pandemic and the associated uncertainties, we were able to guide the company well through the crisis by taking appropriate measures early on,” Nicolas Combé, PhD, the chief financial officer at Formycon AG, said in a statement.
Financially, Formycon was able to perform about as well this past quarter as it did during the same time frame in 2019, earning a total income of €7.2 million (US $8.1 million) by the end of March, which is only €2.3 million (US $2.6 million) less compared to the first quarter of 2019.
Earnings before interest, taxes, depreciation, and amortization amounted to approximately €400,000 (US $450,000), compared to about €500,000 (US $563,000) in the first quarter of 2019.
The operating result (earnings before interest and taxes) was similar between the first quarters of 2019 and 2020, totaling about $225,000 in both. Reported sales revenues resulted from reimbursements for development work in projects licensed out to other companies or developed through a partnership.
For the entirety of 2020, the Formycon expects revenues between €35 million and €40 million (US $39 million and US $45 million).
The Germany-based company was also able to increase employment from 97 employees to 114 compared with the same period in 2019 and is expected to expand that as 2020 continues to progress.
Formycon’s COVID-19 Response
Earlier this year, Formycon had to postpone its annual meeting from May to December in light of the large-scale events ban directed by the German federal government in response to the pandemic.
In April, it announced it was beginning development on COVID-19 biologic drugs using its antibody-based protein drug technology platform, computer-aided structural protein design, and screening tests for SARS-CoV-2—blocking antibody-based drugs.
Formycon’s Biosimilar Pipeline
Formycon currently has 4 biosimilars in its pipeline, with the ranibizumab (FYB201) molecule being the furthest along after completing a phase 3 clinical trial.
The company also has an ustekinumab biosimilar (FYB202) being tested in phase 2 trials and an aflibercept biosimilar (FYB203) in preclinical testing.
The fourth biosimilar, FYB204, currently has no published information or data but was described by Formycon as “an early stage biosimilar project that has been progressed up to the initial cell line screening.”
Etanercept Biosimilar Switch Shows Stable Outcomes and Disease Control in RA
May 13th 2025Patients with rheumatoid arthritis (RA) who switched from Enbrel (reference etanercept) to a biosimilar maintained remission, even after their dose was reduced, with no signs of worsening based on clinical scores, ultrasound scans, or lab tests, according to a new study.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Switching From Avastin to Bevacizumab-bvzr in CRC, NSCLC Can Reduce Medicare Costs
May 10th 2025Monthly savings from fully converting Medicare patients with metastatic colorectal cancer (CRC) and non-squamous metastatic non-small cell lung cancer (NSCLC) from reference bevacizumab to bevacizumab-bvzr could fund 13,887 and 8,959 additional patient-months of treatment, respectively, according to a cost-effectiveness study.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Targeted Reimbursement Encourages Oncology Biosimilar Use
May 7th 2025Incentivizing physicians with modest financial bonuses may seem like a small step, but in Japan’s outpatient oncology setting, it helped push trastuzumab biosimilars toward broader adoption, demonstrating how even limited reimbursement reforms can reshape prescribing behavior under the right conditions.
Oncology Biosimilars Cut Costs; Diabetes and Other Diseases Could Follow
May 6th 2025Shreehas P. Tambe, MD, highlighted the significant potential for biosimilars to expand into other disease areas like diabetes, offering crucial cost-saving solutions amid a rising global burden of noncommunicable diseases.